Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

ViroPharma To Buy Lev For $443 Million

July 21, 2008 | A version of this story appeared in Volume 86, Issue 29

ViroPharma, in Exton, Pa., has reached an agreement to acquire Lev Pharmaceuticals, a New York City-based biopharmaceutical firm focused on developing treatments for inflammatory diseases, for an up-front payment of $442.9 million. Lev's Cinryze, a C1 inhibitor therapy for patients with hereditary angiodema, is currently under FDA review. Lev shareholders are also eligible for up to $175 million in regulatory and commercial milestone payments.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.